June 3, 2015

Listing Department

Bombay Stock Exchange Ltd P.J.Towers, Dalal Street

Mumbai – 400 001 Fax: +91 22 2272 3121 Script Code: SHAS

Listing Department

National Stock Exchange of India Ltd Exchange Plaza, Bandra-Kurla Complex,

Bandra (E)

Mumbai – 400 051 Fax: +91 22 2659 8237 Script Symbol: SHAS

Shasun Pharmaceuticals Limited

3rd & 4th Floor, 'Batra Centre',

28, Sardar Patel Road,

Guindy, Chennai 600032, Tamil Nadu, India.

Tel: +91-44-43446700 Fax: +91-44-22350278

E mail: muralikrishna@shasun.com, shasun@shasun.com

ANNEXURE - 1

Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

Name of the Target Company (TC)	Shasun Pharmaceuticals Limited
Name(s) of the acquirer and Persons	Morgan Stanley Asia (Singapore) Pte
Acting in Concert (PAC) with the acquirer	
Whether the acquirer belongs to	No
Promoter/Promoter group	
Name(s) of the Stock Exchange(s) where	NSE and BSE
the shares of TC are Listed	
	7

After the acquisition, holding of acquirer along with PACs of:	c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired d) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others) e) Total (a+b+c+/-d)	Details of acquisition a) Shares carrying voting rights acquired b) VRs acquired otherwise than by equity shares	 a) Shares carrying voting rights b) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others) c) Voting rights (VR) otherwise than by equity shares d) Warrants/convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) e) Total (a+b+c+d) 	Details of the acquisition as follows Before the acquisition under consideration, holding of acquirer along with PACs of:
	38,923	38,923	2,993,245	Number
	0.0647%	0.0647%	4.9785%	% w.r.t.total share/voting capital wherever applicable(*)
	0.0579%	0.0579%	4.4527%	% w.r.t. total diluted share/voting capital of the TC (**)

a)	Shares carrying voting rights	3,032,168	5.0432%	4.5106%	
1 /	VRs acquired otherwise than by	3,032,100	5.0 15270	1.510070	
"	equity shares				
(2)	Warrants/convertible securities/any				
'	other instrument that entitles the				
	acquirer to receive shares carrying				
8	voting rights in the TC (specify				
	holding in each category) acquired				
d)	Shares in the nature of				
	encumbrance (pledge/ lien/non-				
	disposal undertaking/others)		8		
(e)	Total (a+b+c+d)	3,032,168	5.0432%	4.5106%	
Mode of acquisition (e.g. open market /		Market Purchase			
public issue /rights issue /preferential					
allotment / inter-se transfer, ect)					
Salient features of the securities acquired		N/A			
including time till redemption, ratio at					
which it can be converted in to equity					
shares, etc.		T 1 2015			
Date of acquisition of/ date of receipt of		June 1, 2015			
000.00000000000000000000000000000000000	tion of allotment of shares /VR/				
	ts/convertible securities/any other				
	nent that entitles the acquirer to				
receive shares in the TC		60 102 950			
Equity share capital / total voting capital of		60,123,852			
the TC before the said acquisition		60 123 952			
Equity share capital/ total voting capital of the TC after the said acquisition		60,123,852			
Total diluted share/voting capital of the TC		67,223,852			
10000	e said acquisition	07,223,032			
arici ili	o said acquisition	l			

Signature of the acquirer

Signature of the acquirer / Authorised Signatory Annie Gong, Vice President

Place: Shanghai Date: June 3, 2015

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.